What is new in the management of wet age-related macular degeneration?

British Medical Bulletin

Volumn 105, Issue 1, 2013, Pages 201-211

  Sivaprasad, Sobha ^a   Hykin, Philip ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

aflibercept; age related macular degeneration; bevacizumab; radiation; ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; ANKYRIN; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ARTICLE; BRACHYTHERAPY; CEREBROVASCULAR ACCIDENT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RETINA MACULA AGE RELATED DEGENERATION; VISION; VISUAL ACUITY; AGE RELATED MACULAR DEGENERATION; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG MARKETING; MEDLINE; PHYSICIAN; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; STUDY DESIGN; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; MACULAR DEGENERATION; RADIATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876235734     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldt004     Document Type: Article

References (30)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1.
2. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
3. Funk M, Karl D, Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-9.
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986;104:694-701.
5. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Arch Ophthalmol 2002;120:1443-54.
6. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003;22:721-48.
7. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 2012;6:1175-86.
8. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
9. Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
10. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartin DF, Maguire MG et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
11. Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012 Dec;119:2537-48.
12. Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 2012;130:794-5.
13. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000-2010. Am J Ophthalmol 2012;153:209-13.
14. Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Eye 2012;26:933-6.
15. Arias L, Armada F, Donate J et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009;23:326-33.
16. Muether PS, Hermann MM, Koch K et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011;249:633-7.
17. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
18. IVAN Study Investigators, Chakravarthy U, Harding SP et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
19. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
20. Kruger FM, Kemp H, Sørensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthamol 2013;155:89-95.
21. Hjelmqvist L, Lindberg C, Kanulf P et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011;2011:405724.
22. Mones J. A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. Ophthalmologica 2011;225:112-9.
23. Bressler NM, Boyer DS, Williams DF et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32:1821-8.
24. Antoszyk AN, Tuomi L, Chung CY et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. Am J Ophthalmol 2008;145:862-74.
25. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularization due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-35.
26. Williams PD, Callanan D, Solley W et al. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol 2012;6:1519-25.
27. Kishan AU, Modjtahedi BS, Morse LS et al. Radiation therapy for neovascular age-related macular degeneration. Int J Radiat Oncol Biol Phys. 2012 Sep 10. pii: S0360-3016(12)03296-8. doi: 10.1016/j.ijrobp.2012.07.2352. [Epub ahead of print].
28. Dugel PU, Petrarca R, Bennett M et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology 2012;119:1425-31.
29. Kaiser PK, Cruess AF, Bogaert P et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-71.
30. Maguire MG. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost. LDI Issue Brief 2012;17:1-4.